Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2011 by Universitätsmedizin Mannheim.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Universitätsmedizin Mannheim
ClinicalTrials.gov Identifier:
NCT01345526
First received: April 21, 2011
Last updated: April 28, 2011
Last verified: April 2011

April 21, 2011
April 28, 2011
April 2011
December 2012   (final data collection date for primary outcome measure)
Occurrence of acne-like skin rash grade ≥ 2 (according to the CTCAE version 4.02) during the 8 weeks of skin treatment. [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01345526 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream
A Double Blind Placebo Controlled Randomized Phase II Study Evaluating the Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream in First Line mCRC Patients Treated With Erbitux and FOLFIRI.

The aim of this Phase 2, two-arm, randomized, double blind placebo controlled study is to evaluate the efficacy of combination therapy of doxycycline and Vitamin K1 compared to doxycycline plus placebo for the prevention of acne-like skin rash in mCRC patients receiving first line cetuximab treatment.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Metastatic Colorectal Cancer
  • Device: Reconval K1 Cream
  • Device: Reconval Cream
  • Experimental: Metastatic colorectal cancer, Doxycycline, Vitamin K1 Cream
    Intervention: Device: Reconval K1 Cream
  • Placebo Comparator: Metastatic colorectal cancer, Doxycycline, Cream
    Intervention: Device: Reconval Cream
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
124
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Written informed consent must be given
  • Patient ≥ 18 years
  • Histologically proven and measurable metastatic adenocarcinoma of the colon or rectum (according to modified RECIST criteria v.1.1)
  • Patients eligible for Erbitux and FOLFIRI treatment K-Ras wild type tumour
  • Metastatic disease
  • Life expectancy of at least 12 weeks
  • WHO performance status of 0 or 1
  • Effective contraception for both male and female patients if the risk of conception exists
  • Adequate organ function
  • Adequate bone marrow, hepatic and renal function (Hemoglobin > 10.0 g/dL, platelet count > 100 x 109/L, absolute neutrophil count > 1.5 x 109/L; ALAT, ASAT < 2.5 x ULN (upper limit of normal range) or < 5x ULN in case of liver metastasis; Alkaline phosphatase < 2.5 x ULN; Total bilirubin < 1.5 x ULN; Creatinine clearance > 50 mL/min (calculated according to Cockcroft and Gault formula)).

Exclusion Criteria:

  • Prior treatment for metastatic disease (adjuvant therapy with 5-FU/oxaliplatin based regimens) allowed if stopped 6 months prior to registration on study
  • Prior treatment with EGFR inhibitor
  • Surgery (excluding diagnostic biopsy) or irradiation within 4 weeks prior to study entry
  • Administration of any investigational drug or agent/procedure, i.e. participation in another trial within 4 weeks before beginning treatment with study drugs
  • Concurrent chronic systemic immune therapy, chemotherapy, radiation therapy or hormone therapy not indicated in the study protocol
  • Any active dermatological condition > grade 1 at baseline possibly interfering with or influencing the results or conduct of the present study
  • Brain metastasis (known or suspected)
  • Significant impairment of intestinal resorption (e.g. chronic diarrhea, inflammatory bowel disease)
  • Any other uncontrolled concomitant illness, including serious uncontrolled intercurrent infection
  • Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV, unstable angina pectoris, history of myocardial infarction within the last twelve months, significant arrhythmias)
  • Known allergy or any other adverse reaction to any of the study drugs or to any related compound.
  • Any organ allograft requiring immunosuppressive therapy.
  • Pregnancy (absence to be confirmed by serum/urine beta human chorion gonadotrophin (HCG)) or breast-feeding.
  • Other previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix surgically cured or adequately treated.
  • Known drug abuse / alcohol abuse
  • Legal incapacity or limited legal capacity
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and followup schedule; those conditions should be discussed with the patient before registration in the trial.
  • Medical or psychological condition which, in the opinion of the investigator, would not permit the patient to complete the study or meaningfully sign informed consent.
  • Known M. Meulengracht (Gilbert´s disease) or DPD-insufficiency
  • Known coagulation disorders
  • Ongoing or planned treatment with coumarin derivates
Both
18 Years and older
No
Contact: Ralf Hofheinz, Prof. +49 621 383 2855 Ralf.Hofheinz@umm.de
Germany,   Slovenia
 
NCT01345526
E-VITA
No
Ralf Hofheinz, University Hospital Mannheim
Universitätsmedizin Mannheim
Not Provided
Study Chair: Ralf Hofheinz, Prof. Universitätsmedizin Mannheim
Universitätsmedizin Mannheim
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP